Drug Type Recombinant protein |
Synonyms Haemostasis therapeutic, Haemostat topical, PeproStat + [2] |
Target |
Action stimulants |
Mechanism fibrin stimulants(Fibrin stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Blood Coagulation Disorders | Preclinical | Bosnia and Herzegovina | 31 Mar 2017 | |
Blood Coagulation Disorders | Preclinical | United Kingdom | 31 Mar 2017 | |
Blood Coagulation Disorders | Preclinical | Croatia | 31 Mar 2017 | |
Blood Coagulation Disorders | Preclinical | Poland | 31 Mar 2017 | |
Blood Coagulation Disorders | Preclinical | Serbia | 31 Mar 2017 | |
Hemorrhage | Preclinical | Croatia | 31 Mar 2017 | |
Hemorrhage | Preclinical | United Kingdom | 31 Mar 2017 | |
Hemorrhage | Preclinical | Poland | 31 Mar 2017 | |
Hemorrhage | Preclinical | Serbia | 31 Mar 2017 | |
Hemorrhage | Preclinical | Bosnia and Herzegovina | 31 Mar 2017 |
Phase 2 | 21 | wldmvblsic(ptukpmcwvk) = lyaywtsojt vlwvctuxsu (nomdimmeea ) | - | 20 May 2011 |